Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Core Insights - Adagene Inc. is set to present at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025, focusing on advancements in antibody-based cancer therapies [1][2]. Company Overview - Adagene Inc. is a clinical-stage biotechnology company specializing in the discovery and development of novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [4]. - The company has established strategic collaborations with global partners to enhance its SAFEbody precision masking technology, which is at the forefront of immuno-oncology [4]. Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, aimed at addressing safety and tolerability challenges in antibody therapeutics [5]. - The SAFEbody technology allows for tumor-specific targeting of antibodies while minimizing toxicity to healthy tissues by activating in the tumor microenvironment [5]. - The lead clinical program, ADG126 (muzastotug), is a masked anti-CTLA-4 SAFEbody currently in phase 1b/2 studies, particularly targeting Metastatic Microsatellite-stable Colorectal Cancer [6]. Event Details - The presentation titled "ADG126 SAFEbody: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance" is scheduled for March 26, 2025, from 11:30 AM to 11:50 AM Eastern Time at the Sheraton Boston Hotel [9].